Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 639667 in Healthy Males
NCT02133482Phase 1Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial in rheumatoid arthritis (RA) and multiple sclerosis (MS) comparing BI 639667 with Placebo (2 arms). Primary endpoint: Number of subjects with drug-related adverse events. Planned start Jul 2014; status: withdrawn.
02
Drugs
BI 639667
03
Conditions
rheumatoid arthritis (RA)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02133482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133482.